Phosphorus-32 therapy for cystic craniopharyngiomas

Robert Bryan Barriger, Andrew Chang, Simon S. Lo, Robert D. Timmerman, Colleen DesRosiers, Joel C. Boaz, Achilles J. Fakiris

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background and purpose: To examine control rates for predominantly cystic craniopharyngiomas treated with intracavitary phosphorus-32 (P-32). Material and methods: 22 patients with predominantly cystic craniopharyngiomas were treated at Indiana University between October 1997 and December 2006. Nineteen patients with follow-up of at least 6 months were evaluated. The median patient age was 11 years, median cyst volume was 9 ml, a median dose of 300 Gy was prescribed to the cyst wall, and median follow-up was 62 months. Results: Overall cyst control rate after the initial P-32 treatment was 67%. Complete tumor control after P-32 was 42%. Kaplan-Meier 1-, 3-, and 5-year initial freedom-from- progression rates were 68%, 49%, and 31%, respectively. Following salvage therapy, the Kaplan-Meier 1-, 3-, and 5-year ultimate freedom-from-progression rates were 95%, 95%, and 86%, respectively. All patients were alive at the last follow-up. Visual function was stable or improved in 81% when compared prior to P-32 therapy. Pituitary function remained stable in 74% of patients following P-32 therapy. Conclusions: Intracystic P-32 can be an effective and tolerable treatment for controlling cystic components of craniopharyngiomas as a primary treatment or after prior therapies, but frequently allows for progression of solid tumor components. Disease progression in the form of solid tumor progression, re-accumulation of cystic fluid, or development of new cysts may require further radiotherapy or surgical intervention for optimal long-term disease control.

Original languageEnglish
Pages (from-to)207-212
Number of pages6
JournalRadiotherapy and Oncology
Volume98
Issue number2
DOIs
StatePublished - Feb 2011

Fingerprint

Craniopharyngioma
Phosphorus
Cysts
Therapeutics
Salvage Therapy
Neoplasms
Disease Progression
Radiotherapy

Keywords

  • 32-Phosphorus
  • Brachytherapy
  • Craniopharyngioma

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Hematology

Cite this

Barriger, R. B., Chang, A., Lo, S. S., Timmerman, R. D., DesRosiers, C., Boaz, J. C., & Fakiris, A. J. (2011). Phosphorus-32 therapy for cystic craniopharyngiomas. Radiotherapy and Oncology, 98(2), 207-212. https://doi.org/10.1016/j.radonc.2010.12.001

Phosphorus-32 therapy for cystic craniopharyngiomas. / Barriger, Robert Bryan; Chang, Andrew; Lo, Simon S.; Timmerman, Robert D.; DesRosiers, Colleen; Boaz, Joel C.; Fakiris, Achilles J.

In: Radiotherapy and Oncology, Vol. 98, No. 2, 02.2011, p. 207-212.

Research output: Contribution to journalArticle

Barriger, RB, Chang, A, Lo, SS, Timmerman, RD, DesRosiers, C, Boaz, JC & Fakiris, AJ 2011, 'Phosphorus-32 therapy for cystic craniopharyngiomas', Radiotherapy and Oncology, vol. 98, no. 2, pp. 207-212. https://doi.org/10.1016/j.radonc.2010.12.001
Barriger, Robert Bryan ; Chang, Andrew ; Lo, Simon S. ; Timmerman, Robert D. ; DesRosiers, Colleen ; Boaz, Joel C. ; Fakiris, Achilles J. / Phosphorus-32 therapy for cystic craniopharyngiomas. In: Radiotherapy and Oncology. 2011 ; Vol. 98, No. 2. pp. 207-212.
@article{11534ad13be04b9f95b2d5eb6c6c165c,
title = "Phosphorus-32 therapy for cystic craniopharyngiomas",
abstract = "Background and purpose: To examine control rates for predominantly cystic craniopharyngiomas treated with intracavitary phosphorus-32 (P-32). Material and methods: 22 patients with predominantly cystic craniopharyngiomas were treated at Indiana University between October 1997 and December 2006. Nineteen patients with follow-up of at least 6 months were evaluated. The median patient age was 11 years, median cyst volume was 9 ml, a median dose of 300 Gy was prescribed to the cyst wall, and median follow-up was 62 months. Results: Overall cyst control rate after the initial P-32 treatment was 67{\%}. Complete tumor control after P-32 was 42{\%}. Kaplan-Meier 1-, 3-, and 5-year initial freedom-from- progression rates were 68{\%}, 49{\%}, and 31{\%}, respectively. Following salvage therapy, the Kaplan-Meier 1-, 3-, and 5-year ultimate freedom-from-progression rates were 95{\%}, 95{\%}, and 86{\%}, respectively. All patients were alive at the last follow-up. Visual function was stable or improved in 81{\%} when compared prior to P-32 therapy. Pituitary function remained stable in 74{\%} of patients following P-32 therapy. Conclusions: Intracystic P-32 can be an effective and tolerable treatment for controlling cystic components of craniopharyngiomas as a primary treatment or after prior therapies, but frequently allows for progression of solid tumor components. Disease progression in the form of solid tumor progression, re-accumulation of cystic fluid, or development of new cysts may require further radiotherapy or surgical intervention for optimal long-term disease control.",
keywords = "32-Phosphorus, Brachytherapy, Craniopharyngioma",
author = "Barriger, {Robert Bryan} and Andrew Chang and Lo, {Simon S.} and Timmerman, {Robert D.} and Colleen DesRosiers and Boaz, {Joel C.} and Fakiris, {Achilles J.}",
year = "2011",
month = "2",
doi = "10.1016/j.radonc.2010.12.001",
language = "English",
volume = "98",
pages = "207--212",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Phosphorus-32 therapy for cystic craniopharyngiomas

AU - Barriger, Robert Bryan

AU - Chang, Andrew

AU - Lo, Simon S.

AU - Timmerman, Robert D.

AU - DesRosiers, Colleen

AU - Boaz, Joel C.

AU - Fakiris, Achilles J.

PY - 2011/2

Y1 - 2011/2

N2 - Background and purpose: To examine control rates for predominantly cystic craniopharyngiomas treated with intracavitary phosphorus-32 (P-32). Material and methods: 22 patients with predominantly cystic craniopharyngiomas were treated at Indiana University between October 1997 and December 2006. Nineteen patients with follow-up of at least 6 months were evaluated. The median patient age was 11 years, median cyst volume was 9 ml, a median dose of 300 Gy was prescribed to the cyst wall, and median follow-up was 62 months. Results: Overall cyst control rate after the initial P-32 treatment was 67%. Complete tumor control after P-32 was 42%. Kaplan-Meier 1-, 3-, and 5-year initial freedom-from- progression rates were 68%, 49%, and 31%, respectively. Following salvage therapy, the Kaplan-Meier 1-, 3-, and 5-year ultimate freedom-from-progression rates were 95%, 95%, and 86%, respectively. All patients were alive at the last follow-up. Visual function was stable or improved in 81% when compared prior to P-32 therapy. Pituitary function remained stable in 74% of patients following P-32 therapy. Conclusions: Intracystic P-32 can be an effective and tolerable treatment for controlling cystic components of craniopharyngiomas as a primary treatment or after prior therapies, but frequently allows for progression of solid tumor components. Disease progression in the form of solid tumor progression, re-accumulation of cystic fluid, or development of new cysts may require further radiotherapy or surgical intervention for optimal long-term disease control.

AB - Background and purpose: To examine control rates for predominantly cystic craniopharyngiomas treated with intracavitary phosphorus-32 (P-32). Material and methods: 22 patients with predominantly cystic craniopharyngiomas were treated at Indiana University between October 1997 and December 2006. Nineteen patients with follow-up of at least 6 months were evaluated. The median patient age was 11 years, median cyst volume was 9 ml, a median dose of 300 Gy was prescribed to the cyst wall, and median follow-up was 62 months. Results: Overall cyst control rate after the initial P-32 treatment was 67%. Complete tumor control after P-32 was 42%. Kaplan-Meier 1-, 3-, and 5-year initial freedom-from- progression rates were 68%, 49%, and 31%, respectively. Following salvage therapy, the Kaplan-Meier 1-, 3-, and 5-year ultimate freedom-from-progression rates were 95%, 95%, and 86%, respectively. All patients were alive at the last follow-up. Visual function was stable or improved in 81% when compared prior to P-32 therapy. Pituitary function remained stable in 74% of patients following P-32 therapy. Conclusions: Intracystic P-32 can be an effective and tolerable treatment for controlling cystic components of craniopharyngiomas as a primary treatment or after prior therapies, but frequently allows for progression of solid tumor components. Disease progression in the form of solid tumor progression, re-accumulation of cystic fluid, or development of new cysts may require further radiotherapy or surgical intervention for optimal long-term disease control.

KW - 32-Phosphorus

KW - Brachytherapy

KW - Craniopharyngioma

UR - http://www.scopus.com/inward/record.url?scp=79951858260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951858260&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2010.12.001

DO - 10.1016/j.radonc.2010.12.001

M3 - Article

C2 - 21269713

AN - SCOPUS:79951858260

VL - 98

SP - 207

EP - 212

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 2

ER -